Cargando…
Comparison of SARS-CoV-2 Variants of Concern Alpha (B.1.1.7) vs. Beta (B.1.351) in Critically Ill Patients: A Multicenter Cohort Study
OBJECTIVES: The clinical outcomes of the Beta (B.1.351) variant of concern (VOC) of the SARS-CoV-2 virus remain poorly understood. In early 2021, northeastern France experienced an outbreak of Beta that was not observed elsewhere. This outbreak slightly preceded and then overlapped with a second out...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960192/ https://www.ncbi.nlm.nih.gov/pubmed/35360736 http://dx.doi.org/10.3389/fmed.2022.828402 |
_version_ | 1784677335575822336 |
---|---|
author | Louis, Guillaume Belveyre, Thibaut Goetz, Christophe Gibot, Sébastien Dunand, Paul Conrad, Marie Gaci, Rostane Gette, Sébastien Ouamara, Nadia Perez, Pascale Cadoz, Cyril Picard, Yoann Mellati, Nouchan |
author_facet | Louis, Guillaume Belveyre, Thibaut Goetz, Christophe Gibot, Sébastien Dunand, Paul Conrad, Marie Gaci, Rostane Gette, Sébastien Ouamara, Nadia Perez, Pascale Cadoz, Cyril Picard, Yoann Mellati, Nouchan |
author_sort | Louis, Guillaume |
collection | PubMed |
description | OBJECTIVES: The clinical outcomes of the Beta (B.1.351) variant of concern (VOC) of the SARS-CoV-2 virus remain poorly understood. In early 2021, northeastern France experienced an outbreak of Beta that was not observed elsewhere. This outbreak slightly preceded and then overlapped with a second outbreak of the better understood VOC Alpha (B.1.1.7) in the region. This situation allowed us to contemporaneously compare Alpha and Beta in terms of the characteristics, management, and outcomes of critically ill patients. METHODS: A multicenter prospective cohort study was conducted on all consecutive adult patients who had laboratory confirmed SARS CoV-2 infection, underwent variant screening, and were admitted to one of four intensive care units (ICU) for acute respiratory failure between January 9th and May 15th, 2021. Primary outcome was 60-day mortality. Differences between Alpha and Beta in terms of other outcomes, patient variables, management, and vaccination characteristics were also explored by univariate analysis. The factors that associated with 60-day death in Alpha- and Beta-infected patients were examined with logistic regression analysis. RESULTS: In total, 333 patients (median age, 63 years; 68% male) were enrolled. Of these, 174 and 159 had Alpha and Beta, respectively. The two groups did not differ significantly in terms of 60-day mortality (19 vs. 23%), 28-day mortality (17 vs. 20%), need for mechanical ventilation (60 vs. 61%), mechanical ventilation duration (14 vs. 15 days), other management variables, patient demographic variables, comorbidities, or clinical variables on ICU admission. The vast majority of patients were unvaccinated (94%). The remaining 18 patients had received a partial vaccine course and 2 were fully vaccinated. The vaccinated patients were equally likely to have Alpha and Beta. CONCLUSIONS: Beta did not differ from Alpha in terms of patient characteristics, management, or outcomes in critically ill patients. TRIAL REGISTRATION: ClinicalTrials.gov, identifier: NCT04906850. |
format | Online Article Text |
id | pubmed-8960192 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89601922022-03-30 Comparison of SARS-CoV-2 Variants of Concern Alpha (B.1.1.7) vs. Beta (B.1.351) in Critically Ill Patients: A Multicenter Cohort Study Louis, Guillaume Belveyre, Thibaut Goetz, Christophe Gibot, Sébastien Dunand, Paul Conrad, Marie Gaci, Rostane Gette, Sébastien Ouamara, Nadia Perez, Pascale Cadoz, Cyril Picard, Yoann Mellati, Nouchan Front Med (Lausanne) Medicine OBJECTIVES: The clinical outcomes of the Beta (B.1.351) variant of concern (VOC) of the SARS-CoV-2 virus remain poorly understood. In early 2021, northeastern France experienced an outbreak of Beta that was not observed elsewhere. This outbreak slightly preceded and then overlapped with a second outbreak of the better understood VOC Alpha (B.1.1.7) in the region. This situation allowed us to contemporaneously compare Alpha and Beta in terms of the characteristics, management, and outcomes of critically ill patients. METHODS: A multicenter prospective cohort study was conducted on all consecutive adult patients who had laboratory confirmed SARS CoV-2 infection, underwent variant screening, and were admitted to one of four intensive care units (ICU) for acute respiratory failure between January 9th and May 15th, 2021. Primary outcome was 60-day mortality. Differences between Alpha and Beta in terms of other outcomes, patient variables, management, and vaccination characteristics were also explored by univariate analysis. The factors that associated with 60-day death in Alpha- and Beta-infected patients were examined with logistic regression analysis. RESULTS: In total, 333 patients (median age, 63 years; 68% male) were enrolled. Of these, 174 and 159 had Alpha and Beta, respectively. The two groups did not differ significantly in terms of 60-day mortality (19 vs. 23%), 28-day mortality (17 vs. 20%), need for mechanical ventilation (60 vs. 61%), mechanical ventilation duration (14 vs. 15 days), other management variables, patient demographic variables, comorbidities, or clinical variables on ICU admission. The vast majority of patients were unvaccinated (94%). The remaining 18 patients had received a partial vaccine course and 2 were fully vaccinated. The vaccinated patients were equally likely to have Alpha and Beta. CONCLUSIONS: Beta did not differ from Alpha in terms of patient characteristics, management, or outcomes in critically ill patients. TRIAL REGISTRATION: ClinicalTrials.gov, identifier: NCT04906850. Frontiers Media S.A. 2022-03-10 /pmc/articles/PMC8960192/ /pubmed/35360736 http://dx.doi.org/10.3389/fmed.2022.828402 Text en Copyright © 2022 Louis, Belveyre, Goetz, Gibot, Dunand, Conrad, Gaci, Gette, Ouamara, Perez, Cadoz, Picard and Mellati. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Louis, Guillaume Belveyre, Thibaut Goetz, Christophe Gibot, Sébastien Dunand, Paul Conrad, Marie Gaci, Rostane Gette, Sébastien Ouamara, Nadia Perez, Pascale Cadoz, Cyril Picard, Yoann Mellati, Nouchan Comparison of SARS-CoV-2 Variants of Concern Alpha (B.1.1.7) vs. Beta (B.1.351) in Critically Ill Patients: A Multicenter Cohort Study |
title | Comparison of SARS-CoV-2 Variants of Concern Alpha (B.1.1.7) vs. Beta (B.1.351) in Critically Ill Patients: A Multicenter Cohort Study |
title_full | Comparison of SARS-CoV-2 Variants of Concern Alpha (B.1.1.7) vs. Beta (B.1.351) in Critically Ill Patients: A Multicenter Cohort Study |
title_fullStr | Comparison of SARS-CoV-2 Variants of Concern Alpha (B.1.1.7) vs. Beta (B.1.351) in Critically Ill Patients: A Multicenter Cohort Study |
title_full_unstemmed | Comparison of SARS-CoV-2 Variants of Concern Alpha (B.1.1.7) vs. Beta (B.1.351) in Critically Ill Patients: A Multicenter Cohort Study |
title_short | Comparison of SARS-CoV-2 Variants of Concern Alpha (B.1.1.7) vs. Beta (B.1.351) in Critically Ill Patients: A Multicenter Cohort Study |
title_sort | comparison of sars-cov-2 variants of concern alpha (b.1.1.7) vs. beta (b.1.351) in critically ill patients: a multicenter cohort study |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960192/ https://www.ncbi.nlm.nih.gov/pubmed/35360736 http://dx.doi.org/10.3389/fmed.2022.828402 |
work_keys_str_mv | AT louisguillaume comparisonofsarscov2variantsofconcernalphab117vsbetab1351incriticallyillpatientsamulticentercohortstudy AT belveyrethibaut comparisonofsarscov2variantsofconcernalphab117vsbetab1351incriticallyillpatientsamulticentercohortstudy AT goetzchristophe comparisonofsarscov2variantsofconcernalphab117vsbetab1351incriticallyillpatientsamulticentercohortstudy AT gibotsebastien comparisonofsarscov2variantsofconcernalphab117vsbetab1351incriticallyillpatientsamulticentercohortstudy AT dunandpaul comparisonofsarscov2variantsofconcernalphab117vsbetab1351incriticallyillpatientsamulticentercohortstudy AT conradmarie comparisonofsarscov2variantsofconcernalphab117vsbetab1351incriticallyillpatientsamulticentercohortstudy AT gacirostane comparisonofsarscov2variantsofconcernalphab117vsbetab1351incriticallyillpatientsamulticentercohortstudy AT gettesebastien comparisonofsarscov2variantsofconcernalphab117vsbetab1351incriticallyillpatientsamulticentercohortstudy AT ouamaranadia comparisonofsarscov2variantsofconcernalphab117vsbetab1351incriticallyillpatientsamulticentercohortstudy AT perezpascale comparisonofsarscov2variantsofconcernalphab117vsbetab1351incriticallyillpatientsamulticentercohortstudy AT cadozcyril comparisonofsarscov2variantsofconcernalphab117vsbetab1351incriticallyillpatientsamulticentercohortstudy AT picardyoann comparisonofsarscov2variantsofconcernalphab117vsbetab1351incriticallyillpatientsamulticentercohortstudy AT mellatinouchan comparisonofsarscov2variantsofconcernalphab117vsbetab1351incriticallyillpatientsamulticentercohortstudy |